Health care providers and direct-to-consumer access and advertising of genetic testing in the United States

Genome Medicine

Volumn 3, Issue 12, 2011, Pages

  Myers, Melanie F ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERTIZING; CLINICAL GENETICS; CONSUMER; GENETIC ANALYSIS; GENETIC SCREENING; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HUMAN; MARKETING; MOLECULAR GENETICS; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 84855190062     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm297     Document Type: Review

References (149)

1. Sufrin CB, Ross JS. Pharmaceutical industry marketing: understanding its impact on women's health. Obstet Gynecol Surv 2008, 63:585-596.
2. Kaiser Family Foundation Impact of direct-to-consumer advertising on prescription drug spending. 2003, Kaiser Family Foundation Publication #6084, Kaiser Family Foundation., http://www.kff.org/
3. Liang BA, Mackey T. Direct-to-consumer advertising with interactive internet media: global regulation and public health issues. JAMA 2011, 305:824-825.
4. U.S. Food and Drug Administration Guidance for industry consumer-directed broadcast advertisements. 1999, FDA, U.S. Food and Drug Administration., http://www.fda.gov/RegulatoryInformation/Guidances/ucm125039.htm
5. Beales JH, Pahl TB, Montague RC, Eichorn LM, Froeb L, Ippolito PM, Mulholland JP, Zywicki TJ, Ohlhausen MK. In the matter of request for comments on agency draft guidance documents regarding consumer-directed promotion. Bureau of Consumer Protection (docket no. 2004D-0042) 2004, , http://www.fda.gov/ohrms/dockets/dailys/04/sep04/091604/04D-0042-EC11-02-T2525-Attach-1.pdf
6. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. Promotion of prescription drugs to consumers. N Engl J Med 2002, 346:498-505.
7. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med 2007, 357:673-681.
8. Borry P, Cornel MC, Howard HC. Where are you going, where have you been: a recent history of the direct-to-consumer genetic testing market. J Community Genet 2010, 1:101-106.
9. US Food and Drug Administration Meeting Materials of the Molecular and Clinical Genetics Panel. 2011, FDA, US Food and Drug Administration., http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/MolecularandClinicalGeneticsPanel/ucm245447.htm
10. Janssens AC, Gwinn M, Bradley LA, Oostra BA, van Duijn CM, Khoury MJ. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet 2008, 82:593-599.
11. Genetics and Public Policy Center GPPC releases updated list of DTC genetic testing companies. 2001, Genetics and Public Policy Center, Genetics and Public Policy Center., http://www.dnapolicy.org/news.release.php?action=detail&pressrelease_id=145
12. Samuel GN, Jordens CF, Kerridge I. Direct-to-consumer personal genome testing: ethical and regulatory issues that arise from wanting to 'know' your DNA. Intern Med J 2010, 40:220-224.
13. Hogarth S, Javitt G, Melzer D. The current landscape for direct-to-consumer genetic testing: legal, ethical, and policy issues. Annu Rev Genomics Hum Genet 2008, 9:161-182.
14. Kaye J. The regulation of direct-to-consumer genetic tests. Hum Mol Genet 2008, 17(R2):R180-183.
15. McBride CM, Wade CH, Kaphingst KA. Consumers' views of direct-to-consumer genetic information. Annu Rev Genomics Hum Genet 2010, 11:427-446.
16. Kessler DA, Levy DA. Direct-to-consumer advertising: is it too late to manage the risks?. Ann Fam Med 2007, 5:4-5.
17. Mansfield PR, Mintzes B, Richards D, Toop L. Direct to consumer advertising. BMJ 2005, 330:5-6.
18. Hollon MF. Direct-to-consumer advertising: a haphazard approach to health promotion. JAMA 2005, 293:2030-2033.
19. Hollon MF. Direct-to-consumer marketing of prescription drugs: creating consumer demand. JAMA 1999, 281:382-384.
20. Holmer AF. Direct-to-consumer advertising - strengthening our health care system. N Engl J Med 2002, 346:526-528.
21. Holmer AF. Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA 1999, 281:380-382.
22. Rosenberg L. Does direct-to-consumer marketing of medical technologies undermine the physician-patient relationship?. Am J Bioeth 2009, 9:22-23.
23. Wilkes MS, Bell RA, Kravitz RL. Direct-to-consumer prescription drug advertising: trends, impact, and implications. Health Aff 2000, 19:110-128.
24. Weissman JS, Blumenthal D, Silk AJ, Newman M, Zapert K, Leitman R, Feibelmann S. Physicians report on patient encounters involving direct-to-consumer advertising. Health Aff 2004, (Suppl Web Exclusives). W4-219-233.
25. Mintzes B, Barer ML, Kravitz RL, Bassett K, Lexchin J, Kazanjian A, Evans RG, Pan R, Marion SA. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ 2003, 169:405-412.
26. Mintzes B, Barer ML, Kravitz RL, Kazanjian A, Bassett K, Lexchin J, Evans RG, Pan R, Marion SA. Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ 2002, 324:278-279.
27. Spence MM, Teleki SS, Cheetham TC, Schweitzer SO, Millares M. Direct-to-consumer advertising of COX-2 inhibitors: effect on appropriateness of prescribing. Med Care Res Rev 2005, 62:544-559.
28. Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, Hinton L, Franks P. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA 2005, 293:1995-2002.
29. Robinson AR, Hohmann KB, Rifkin JI, Topp D, Gilroy CM, Pickard JA, Anderson RJ. Direct-to-consumer pharmaceutical advertising: physician and public opinion and potential effects on the physician-patient relationship. Arch Intern Med 2004, 164:427-432.
30. Aiken K, Swasy J, Braman A. Patient and Physician Attitudes and Behaviors Associated with DTC Promotion of Prescription Drugs: Summary of FDA Survey Research Results. 2004, US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research., http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/DrugMarketingAdvertisingandCommunicationsResearch/UCM152890.pdf
31. Kaphingst KA, DeJong W. The educational potential of direct-to-consumer prescription drug advertising. Health Aff 2004, 23:143-150.
32. Frosch DL, Krueger PM, Hornik RC, Cronholm PF, Barg FK. Creating demand for prescription drugs: a content analysis of television direct-to-consumer advertising. Ann Fam Med 2007, 5:6-13.
33. Bell RA, Kravitz RL, Wilkes MS. Direct-to-consumer prescription drug advertising and the public. J Gen Intern Med 1999, 14:651-657.
34. Kaiser Family Foundation Understanding the effects of direct-to-consumer prescription drug advertising. 2001, Kaiser Family Foundation Publication, Kaiser Family Foundation., http://www.kff.org/
35. Block AE. Costs and benefits of direct-to-consumer advertising: the case of depression. Pharmacoeconomics 2007, 25:511-521.
36. Price RA, Frank RG, Cleary PD, Goldie SJ. Effects of direct-to-consumer advertising and clinical guidelines on appropriate use of human papillomavirus DNA tests. Med Care 2011, 49:132-138.
37. Lee D, Begley CE. Racial and ethnic disparities in response to direct-to-consumer advertising. Am J Health Syst Pharm 2010, 67:1185-1190.
38. Lachance CR, Erby LA, Ford BM, Allen VC, Kaphingst KA. Informational content, literacy demands, and usability of websites offering health-related genetic tests directly to consumers. Genet Med 2010, 12:304-312.
39. Gollust SE, Hull SC, Wilfond BS. Limitations of direct-to-consumer advertising for clinical genetic testing. JAMA 2002, 288:1762-1767.
40. Leighton JW, Valverde K, Bernhardt BA. The general public's understanding and perception of direct-to-consumer genetic test results. Public Health Genomics 2012, 15:11-21.
41. Bloss CS, Darst BF, Topol EJ, Schork NJ. Direct-to-consumer personalized genomic testing. Hum Mol Genet 2011, 20:R132-141.
42. Bunnik E, Janssens AC, Schermer M. How attitudes research contributes to overoptimistic expectations of personal genome testing. Am J Bioeth 2009, 9:23-25.
43. McGuire AL, Burke W. An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. JAMA 2008, 300:2669-2671.
44. Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the bottle - will we get our wish?. N Engl J Med 2008, 358:105-107.
45. Myers MF, Chang MH, Jorgensen C, Whitworth W, Kassim S, Litch JA, Armstrong L, Bernhardt B, Faucett WA, Irwin D, Mouchawar J, Bradley LA. Genetic testing for susceptibility to breast and ovarian cancer: evaluating the impact of a direct-to-consumer marketing campaign on physicians' knowledge and practices. Genet Med 2006, 8:361-370.
46. Centers for Disease Control and Prevention Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing - Atlanta, Denver, Raleigh-Durham, and Seattle, 2003. MMWR Morb Mortal Wkly Rep 2004, 53:603-606. Centers for Disease Control and Prevention.
47. Mouchawar J, Hensley-Alford S, Laurion S, Ellis J, Kulchak-Rahm A, Finucane ML, Meenan R, Axell L, Pollack R, Ritzwoller D. Impact of direct-to-consumer advertising for hereditary breast cancer testing on genetic services at a managed care organization: a naturally-occurring experiment. Genet Med 2005, 7:191-197.
48. Geransar R, Einsiedel E. Evaluating online direct-to-consumer marketing of genetic tests: informed choices or buyers beware?. Genet Test 2008, 12:13-23.
49. Bowen DJ, Harris J, Jorgensen CM, Myers MF, Kuniyuki A. Socioeconomic influences on the effects of a genetic testing direct-to-consumer marketing campaign. Public Health Genomics 2010, 13:131-142.
50. Ortiz AP, Lopez M, Flores LT, Soto-Salgado M, Finney Rutten LJ, Serrano-Rodriguez RA, Hesse BW, Tortolero-Luna G. Awareness of direct-to-consumer genetic tests and use of genetic tests among Puerto Rican adults, 2009. Prev Chronic Dis 2011, 8:A110.
51. Imai K, Kricka LJ, Fortina P. Concordance study of 3 direct-to-consumer genetic-testing services. Clin Chem 2011, 57:518-521.
52. Ng PC, Murray SS, Levy S, Venter JC. An agenda for personalized medicine. Nature 2009, 461:724-726.
53. Swan M. Multigenic condition risk assessment in direct-to-consumer genomic services. Genet Med 2010, 12:279-288.
54. Kutz G. Direct to consumer genetic tests: misleading test results are further complicated by deceptive marketing and other questionable practices. 2010, US Government Accountability Office., http://www.gao.gov/new.items/d10847t.pdf
55. Kraft P, Hunter DJ. Genetic risk prediction - are we there yet?. N Engl J Med 2009, 360:1701-1703.
56. Mennuti M. Are doctors prepared for direct-to-consumer advertising of genetic tests?. Obstet Gynecol 2008, 111:991. author reply 991.
57. Secretary's Advisory Committee on Genetics, Health and Society U.S. system of oversight of genetic testing: a response to the charge of the Secretary of Health and Human Services. 2008, US Department of Health and Human Services, Secretary's Advisory Committee on Genetics, Health and Society., http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS_oversight_report.pdf
58. Feero WG, Green ED. Genomics education for health care professionals in the 21st century. JAMA 2011, 306:989-990.
59. Wolfberg AJ. Genes on the Web - direct-to-consumer marketing of genetic testing. N Engl J Med 2006, 355:543-545.
60. Gray S, Olopade OI. Direct-to-consumer marketing of genetic tests for cancer: buyer beware. J Clin Oncol 2003, 21:3191-3193.
61. Hudson KL, Holohan MK, Collins FS. Keeping pace with the times - the Genetic Information Nondiscrimination Act of 2008. N Engl J Med 2008, 358:2661-2663.
62. U.S. Department of Health and Human Services "GINA" The Genetic Information Nondiscrimination Act of 2008: information for research and health care professionals. 2009, US Department of Health and Human Services, U.S. Department of Health and Human Services., http://www.genome.gov/Pages/PolicyEthics/GeneticDiscrimination/GINAInfoDoc.pdf
63. Gollust SE, Wilfond BS, Hull SC. Direct-to-consumer sales of genetic services on the internet. Genet Med 2003, 5:332-337.
64. Genetics and Public Policy Center Direct-to-consumer genetic testing companies. 2009, Genetics and Public Policy Center, Genetics and Public Policy Center., http://www.dnapolicy.org/resources/DTCcompanieslist.pdf
65. U.S. Food and Drug Administration Letters to manufacturers concerning genetic tests U.S. Food and Drug Administration., http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm219582.htm
66. US Food and Drug Administration Letters to industry US Food and Drug Administration., http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/ucm111104.htm
67. US Federal Trade Commission Guidance documents: advertising policy statements, US Federal Trade Commission., http://www.ftc.gov/bcp/menus/resources/guidance/adv.shtm
68. Javitt GH, Hudson K. Federal neglect: regulation of genetic testing. Issues Sci Technol 2006, Spring:59-66.
69. Federal Trade Commission FTC facts for consumers: at-home genetic tests: a healthy dose of skepticism may be the best prescription. 2006, Federal Trade Commission, Federal Trade Commission., http://www.ftc.gov/bcp/edu/pubs/consumer/health/hea02.shtm
70. Federal Trade Commission Genelex Corporation, FTC File No. 072-3128. 2009, Federal Trade Commission, Federal Trade Commission., http://www.ftc.gov/os/closings/090814genelexclosingletter.pdf
71. Federal Trade Commission Sciona, Inc., FTC File No. 072-3127. 2009, Federal Trade Commission, Federal Trade Commission., http://www.ftc.gov/os/closings/090814scionaclosingletter.pdf
72. Centers for Medicare & Medicaid Services Clinical laboratory improvement amendments (CLIA). Centers for Medicare & Medicaid Services., https://www.cms.gov/clia/
73. Shuren J. Direct to consumer genetic testing and the consequences to the public. Food and Drug Administration 2010, , http://www.fda.gov/NewsEvents/Testimony/ucm219925.htm
74. Chen B, Gagnon M, Shahangian S, Anderson NL, Howerton DA, Boone JD. Good laboratory practices for molecular genetic testing for heritable diseases and conditions. MMWR Recomm Rep 2009, 58:1-37. quiz CE: 31-34.
75. Hudson KL, Murphy JA, Kaufman DJ, Javitt GH, Katsanis SH, Scott J. Oversight of US genetic testing laboratories. Nat Biotechnol 2006, 24:1083-1090.
76. McGovern MM, Elles R, Beretta I, Somerville MJ, Hoefler G, Keinanen M, Barton D, Carson N, Dequeker E, Brdicka R, Blazkova A, Aymé S, Schnieders B, Muller CR, Dalen V, Martinez AA, Kristoffersson U, Ozguc M, Mueller H, Boone J, Lubin IM, Sequeiros J, Taruscio D, Williamson B, Mainland L, Yoshikura H, Ronchi E. Report of an international survey of molecular genetic testing laboratories. Community Genet 2007, 10:123-131.
77. Genetics and Public Policy Center Survey of direct to consumer testing statutes and regulation. 2007, Genetics and Public Policy Center, Genetics and Public Policy Center., http://www.dnapolicy.org/resources/DTCStateLawChart.pdf
78. Liang BA, Mackey TK. Prevalence and global health implications of social media in direct-to-consumer drug advertising. J Med Internet Res 2011, 13:e64.
79. Williams-Jones B. Where there's a web, there's a way: commercial genetic testing and the internet. Community Genet 2003, 6:46-57.
80. Mihaescu R, van Hoek M, Sijbrands EJ, Uitterlinden AG, Witteman JC, Hofman A, van Duijn CM, Janssens AC. Evaluation of risk prediction updates from commercial genome-wide scans. Genet Med 2009, 11:588-594.
81. Burke W, Laberge AM, Press N. Debating clinical utility. Public Health Genomics 2010, 13:215-223.
82. Khoury MJ, McBride CM, Schully SD, Ioannidis JP, Feero WG, Janssens AC, Gwinn M, Simons-Morton DG, Bernhardt JM, Cargill M, Chanock SJ, Church GM, Coates RJ, Collins FS, Croyle RT, Davis BR, Downing GJ, Duross A, Friedman S, Gail MH, Ginsburg GS, Green RC, Greene MH, Greenland P, Gulcher JR, Hsu A, Hudson KL, Kardia SL, Kimmel PL, Lauer MS, et al. The Scientific Foundation for Personal Genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med 2009, 11:559-567.
83. Kuehn BM. Risks and benefits of direct-to-consumer genetic testing remain unclear. JAMA 2008, 300:1503-1505.
84. McGuire AL, Evans BJ, Caulfield T, Burke W. Science and regulation. Regulating direct-to-consumer personal genome testing. Science 2010, 330:181-182.
85. Kutz G. Nutrigenetic testing: tests purchased from four web sites mislead consumers. 2006, US Government Accountability Ofiice., http://www.gao.gov/new.items/d06977t.pdf
86. Evaluation of Genomic Applications in Practice and Prevention EGAPP Previews, Evaluation of Genomic Applications in Practice and Prevention., http://www.egappreviews.org
87. Secretary's Advisory Committee on Genetics, Health and Society Direct-to-consumer genetic testing. 2010, US Department of Health and Human Services, Secretary's Advisory Committee on Genetics, Health and Society., http://oba.od.nih.gov/oba/sacghs/reports/SACGHS_DTC_Report_2010.pdf
88. Magnus D, Cho MK, Cook-Deegan R. Direct-to-consumer genetic tests: beyond medical regulation?. Genome Med 2009, 1:17.
89. Wright CF, Hall A, Zimmern RL. Regulating direct-to-consumer genetic tests: what is all the fuss about?. Genet Med 2011, 13:295-300.
90. Caulfield T. Direct-to-consumer testing: if consumers are not anxious, why are policymakers?. Hum Genet 2011, 130:23-25.
91. Javitt GH. Pink or blue? The need for regulation is black and white. Fertil Steril 2006, 86:13-15.
92. Hutchison C. Over-the-counter DNA testing: wave of the future or waste of money?. ABC news 2010, , http://abcnews.go.com/Health/Wellness/dna-screening-home-coming-walgreens/story?id=10614580
93. US Food and Drug Administration FDA/CDRH public meeting: oversight of laboratory developed tests (LDTs), date July 19-20, 2010. 2010, U.S. Food and Drug Administration, US Food and Drug Administration., http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm212830.htm
94. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010, 363:301-304.
95. US Food and Drug Administration Town hall discussion with the Director of CDRH and other senior center management, September 22, 2011. 2011, US Food and Drug Administration, US Food and Drug Administration., http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm258228.htm#transcript
96. Kolor K, Liu T, St Pierre J, Khoury MJ. Health care provider and consumer awareness, perceptions, and use of direct-to-consumer personal genomic tests, United States, 2008. Genet Med 2009, 11:595.
97. Goddard KA, Duquette D, Zlot A, Johnson J, Annis-Emeott A, Lee PW, Bland MP, Edwards KL, Oehlke K, Giles RT, Rafferty A, Cook ML, Khoury MJ. Public awareness and use of direct-to-consumer genetic tests: results from 3 state population-based surveys, 2006. Am J Public Health 2009, 99:442-445.
98. Bloss CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med 2011, 364:524-534.
99. Stack CB, Gharani N, Gordon ES, Schmidlen T, Christman MF, Keller MA. Genetic risk estimation in the Coriell personalized medicine collaborative. Genet Med 13:131-139.
100. The multiplex initiative. , https://www.multiplex.nih.gov/
101. McBride CM, Alford SH, Reid RJ, Larson EB, Baxevanis AD, Brody LC. Characteristics of users of online personalized genomic risk assessments: implications for physician-patient interactions. Genet Med 2009, 11:582-587.
102. Gollust SE, Gordon ES, Zayac C, Griffin G, Christman MF, Pyeritz RE, Wawak L, Bernhardt BA. Motivations and perceptions of early adopters of personalized genomics: perspectives from research participants. Public Health Genomics 2012, 15:22-30.
103. Bloss CS, Ornowski L, Silver E, Cargill M, Vanier V, Schork NJ, Topol EJ. Consumer perceptions of direct-to-consumer personalized genomic risk assessments. Genet Med 2010, 12:556-566.
104. Marteau TM, French DP, Griffin SJ, Prevost AT, Sutton S, Watkinson C, Attwood S, Hollands GJ. Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours. Cochrane Database Syst Rev 2010, CD007275.
105. Collins RE, Wright AJ, Marteau TM. Impact of communicating personalized genetic risk information on perceived control over the risk: a systematic review. Genet Med 2011, 13:273-277.
106. Kaufman D, Murphy Bollinger J, Devaney S, Scott J. Direct from consumers: a survey of 1,048 customers of three direct-to-consumer personal genomic testing companies about motivations, attitudes, and responses to testing. Presented at the American Society of Human Genetics 60th Annual Meeting: November 2-6 2010; Washington, DC. ASHG 2010, , http://www.ashg.org/cgi-bin/2010/ashg10s?author=Kaufman%20D&sort=ptimes&sbutton=Detail&absno=21043&sid=305615
107. Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC. Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL study. Alzheimer Dis Assoc Disord 2008, 22:94-97.
108. Wijdenes-Pijl M, Dondorp WJ, Timmermans DR, Cornel MC, Henneman L. Lay perceptions of predictive testing for diabetes based on DNA test results versus family history assessment: a focus group study. BMC Public Health 2011, 11:535.
109. Wilde A, Meiser B, Mitchell PB, Schofield PR. Public interest in predictive genetic testing, including direct-to-consumer testing, for susceptibility to major depression: preliminary findings. Eur J Hum Genet 2010, 18:47-51.
110. McGuire AL, Diaz CM, Wang T, Hilsenbeck SG. Social networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth 2009, 9:3-10.
111. Tracy EE. Are doctors prepared for direct-to-consumer advertising of genetics tests?. Obstet Gynecol 2007, 110:1389-1391.
112. McGuire AL, Burke W. Health system implications of direct-to-consumer personal genome testing. Public Health Genomics 2011, 14:53-58.
113. Caulfield TA. The informed gatekeeper?: a commentary on genetic tests, marketing pressure and the role of primary care physicians. Health Law Rev 2001, 9:14-18.
114. Culver JO, Hull JL, Dunne DF, Burke W. Oncologists' opinions on genetic testing for breast and ovarian cancer. Genet Med 2001, 3:120-125.
115. Vadaparampil ST, Wideroff L, Olson L, Viswanath K, Freedman AN. Physician exposure to and attitudes toward advertisements for genetic tests for inherited cancer susceptibility. Am J Med Genet A 2005, 135:41-46.
116. Myriad Genetics Inc. Myriad Genetics launches public awareness campaign in five midwest states to reach women with increased risk of hereditary breast and ovarian cancer. 2009, Myriad Genetics Inc., Myriad Genetics Inc.., http://investor.myriad.com/releasedetail.cfm?ReleaseID=408932
117. Myriad Genetics Inc. Myriad Genetics Launches Awareness Advertising Campaign to Educate Women About Hereditary Risks of Breast and Ovarian Cancers. 2007, Myriad Genetics Inc., Myriad Genetics Inc.., http://investor.myriad.com/releasedetail.cfm?ReleaseID=325769
118. Myriad Genetics Inc. Myriad Genetics Reports Results for Third Quarter of Fiscal 2008. 2008, Myriad Genetics Inc, Myriad Genetics Inc.., http://investor.myriad.com/releasedetail.cfm?ReleaseID=325474
119. Mouchawar J, Laurion S, Ritzwoller DP, Ellis J, Kulchak-Rahm A, Hensley-Alford S. Assessing controversial direct-to-consumer advertising for hereditary breast cancer testing: reactions from women and their physicians in a managed care organization. Am J Manag Care 2005, 11:601-608.
120. Powell KP, Cogswell WA, Christianson CA, Dave G, Verma A, Eubanks S, Henrich VC. Primary care physicians' awareness, experience and opinions of direct-to-consumer genetic testing. J Genet Couns 2011, doi: 10.1007/s10897-011-9390-9.
121. Ohata T, Tsuchiya A, Watanabe M, Sumida T, Takada F. Physicians' opinion for 'new' genetic testing in Japan. J Hum Genet 2009, 54:203-208.
122. Jordens CF, Kerridge IH, Samuel GN. Direct-to-consumer personal genome testing: the problem is not ignorance - it is market failure. Am J Bioeth 2009, 9:13-15.
123. Hock KT, Christensen KD, Yashar BM, Roberts JS, Gollust SE, Uhlmann WR. Direct-to-consumer genetic testing: an assessment of genetic counselors' knowledge and beliefs. Genet Med 2011, 13:325-332.
124. Giovanni MA, Fickie MR, Lehmann LS, Green RC, Meckley LM, Veenstra D, Murray MF. Health-care referrals from direct-to-consumer genetic testing. Genet Test Mol Biomarkers 2010, 14:817-819.
125. Haga SB, Carrig MM, O'Daniel JM, Orlando LA, Killeya-Jones LA, Ginsburg GS, Cho A. Genomic risk profiling: attitudes and use in personal and clinical care of primary care physicians who offer risk profiling. J Gen Intern Med 26:834-840.
126. Ormond KE, Hudgins L, Ladd JM, Magnus DM, Greely HT, Cho MK. Medical and graduate students' attitudes toward personal genomics. Genet Med 2011, 13:400-408.
127. Perez GK, Cruess DG, Cruess S, Brewer M, Stroop J, Schwartz R, Greenstein R. Attitudes toward direct-to-consumer advertisements and online genetic testing among high-risk women participating in a hereditary cancer clinic. J Health Commun 2011, 16:607-628.
128. Guttmacher AE, Porteous ME, McInerney JD. Educating health-care professionals about genetics and genomics. Nat Rev Genet 2007, 8:151-157.
129. Bellcross CA, Kolor K, Goddard KA, Coates RJ, Reyes M, Khoury MJ. Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians. Am J Prev Med 2011, 40:61-66.
130. Baars MJ, Henneman L, Ten Kate LP. Deficiency of knowledge of genetics and genetic tests among general practitioners, gynecologists, and pediatricians: a global problem. Genet Med 2005, 7:605-610.
131. Sharp RR, Goldlust ME, Eng C. Addressing gaps in physician education using personal genomic testing. Genet Med 13:750-751.
132. Walt DR, Kuhlik A, Epstein SK, Demmer LA, Knight M, Chelmow D, Rosenblatt M, Bianchi DW. Lessons learned from the introduction of personalized genotyping into a medical school curriculum. Genet Med 2011, 13:63-66.
133. European Society of Human Genetics Statement of the ESHG on direct-to-consumer genetic testing for health-related purposes. Eur J Hum Genet 2010, 18:1271-1273. European Society of Human Genetics.
134. Hudson K, Javitt G, Burke W, Byers P. ASHG statement on direct-to-consumer genetic testing in the United States. Obstet Gynecol 2007, 110:1392-1395.
135. National Society of Genetic Counselors Direct to consumer genetic testing. 2007, NSGC, revised 2011, National Society of Genetic Counselors., http://www.nsgc.org/Advocacy/PositionStatements/tabid/107/Default.aspx#DTC
136. Ameer B, Krivoy N. Direct-to-consumer/patient advertising of genetic testing: a position statement of the American College of Clinical Pharmacology. J Clin Pharmacol 2009, 49:886-888.
137. Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010, 28:893-901.
138. American Medical Association Direct-to-consumer genetic testing. American Medical Association., http://www.ama-assn.org/resources/doc/genetics/dtc-genetic-test.pdf
139. Human Genetics Commission A common framework of principles for direct-to-consumer genetic testing services. Human Genetics Commission., http://www.hgc.gov.uk/Client/Content.asp?ContentId=816
140. American College of Medical Genetics ACMG statement on direct-to-consumer genetic testing, American College of Medical Genetics., http://www.acmg.net/StaticContent/StaticPages/DTC_Statement.pdf
141. American College of Obstetricians and Gynecologists ACOG Committee Opinion No. 409: direct-to-consumer marketing of genetic testing. Obstet Gynecol 2008, 111:1493-1494. American College of Obstetricians and Gynecologists.
142. Human Genetics Society of Australasia Issue paper: direct to consumer genetic testing. 2007, HGSA, Human Genetics Society of Australasia., https://www.hgsa.org.au/website/wp-content/uploads/2009/12/2007-IP01-4517.pdf
143. Nelson T, Armstrong L, Richer J, Evans J, Lauzon J, McGillivray B, Bruyere H, Dougan S. CCMG statement on direct-to-consumer genetic testing. Clin Genet 2011, doi: 10.1111/j.1399-0004.2011.01789.x.
144. Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ 1997, 157:408-416.
145. Secretary's Advisory Committee on Genetics, Health and Society Genetics education and training. 2011, US Department of Health and Human Services, Secretary's Advisory Committee on Genetics, Health and Society., http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS_education_report_2011.pdf
146. The Human Genome Interpretation Company. , http://knome.com/
147. Ambry Genetics. , http://ambrygen.com/
148. Borry P, Howard HC, Senecal K, Avard D. Health-related direct-to-consumer genetic testing: a review of companies' policies with regard to genetic testing in minors. Fam Cancer 2010, 9:51-59.
149. Howard HC, Avard D, Borry P. Are the kids really all right? Direct-to-consumer genetic testing in children: are company policies clashing with professional norms?. Eur J Hum Genet 2011, 19:1122-1126.